A First in Human Feasibility Study to Evaluate the Safety and Effectiveness of the BIOTRONIK Prospera SCS System With HomeStream Remote Management

Chronic Low-back Pain Clinical Trial

Official title:

BENEFIT-03 Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04683718
• Other study ID #: BENEFIT-03
• Status: Recruiting
• Phase: N/A
• Start date: September 20, 2021
• Est. completion date: February 2026

Study information

• Verified date: October 2023
• Source: Biotronik, Inc.
• Contact: Justin Michalski
• Phone: (503)927-7230
• Email: benefit03[@]biotronik.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The BENEFIT-03 Clinical Study is a first in human, prospective, multi-center, single-arm, interventional feasibility study to be conducted in Australia. The purpose of the BENEFIT-03 study is to collect initial safety and effectiveness data on the BIOTRONIK Prosper SCS (Spinal Cord Stimulation) System with HomeStream Remote Management. Enrolled participants will complete a SCS trial period per the standard of care utilizing the BIOTRONIK Resilience percutaneous SCS trial leads and the BIOTRONIK Prospera External Pulse Generator (EPG). Following a successful trial period, participants will be implanted with a permanent BIOTRONIK Prospera Implantable Pulse Generator (IPG). Implanted participants will be followed for 24 months post-implant with in-office visits and remote management visits.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 2026
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Currently indicated for SCS therapy for the treatment of low back and/or leg pain
• Planned permanent implant of BIOTRONIK's Prospera SCS System with HomeStream Remote Management
• Planned placement of two BIOTRONIK Resilience SCS trial leads
• Documented scores of = 60 mm out of 100 mm on the Visual Analog Scale (VAS) for both overall pain intensity and pain intensity in the index area of pain, assessed at the time of enrollment
• Willing and able to comply with all study requirements, including all required procedures, phone and/or video calls, and study visits
• Age greater than or equal to 18 years and less than 80 years
• Able to understand the nature of the study and provide written informed consent
• Able to read, understand, and speak English
• Patient's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation
• Oswestry Disability Index (ODI) score of 41 to 80 out of 100
• Passed psychological evaluation
• For diabetic patients: minimum of one HbA1c test within the last 6 months, with most recent result = 8.0%

Exclusion Criteria:

• Any contraindication for SCS therapy
• Patients with an implanted pacemaker, defibrillator, or any other medical contraindication for SCS therapy
• Currently implanted with an infusion pump or any implantable neurostimulator device
• Previously implanted with a neurostimulation system or prior participation in a trial period for a neurostimulation system
• Currently enrolled in any investigational device or drug trial for the management of chronic pain
• Patients who have undergone spinal surgery within 12 months prior to enrollment
• Patients currently involved in an active WorkCover insurance claim and/or active litigation related to injury associated with indication for SCS
• Patients with a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency (other than prescribed) in the 6 months prior to enrollment
• Patients currently displaying opioid-seeking behavior
• Presence of any life-threatening, underlying illness
• Life expectancy less than 1 year
• Patients reporting pregnancy at the time of enrollment or intending to become pregnant during the 2-year study duration
• Patients with opioid dosages > 120 morphine milligram equivalents (MME) per day
• Patients with poor compliance for pain management regimen
• Patients with a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the investigator
• Patients with pain originating from peripheral vascular disease
• Current diagnosis of a coagulation disorder or bleeding diathesis
• Patients with a diagnosis of severe thoracic scoliosis that is likely to preclude SCS lead placement
• Patients who are immunocompromised and/or at high risk for infection
• Patients with a documented history of allergic response or sensitivity to material(s) required for the study (e.g. adhesives, titanium, silicone, etc.) At the conclusion of the trial period, the absence of the following exclusion criteria

should be confirmed before proceeding with the permanent Prospera SCS System implant:

• Reduction in overall pain of less than 50% from baseline, assessed using VAS
• Unsuccessful trial period as otherwise determined by the investigator
• Determined by the investigator to be a poor candidate for permanent Prospera SCS System implant per standard of care (e.g. due to infection, non-compliance with pain medication regimen, paresis, clumsiness, numbness, and other) Additionally, pre-operative screening for staphylococcus aureus (MRSA/MSSA) must be conducted after the SCS trial period and prior to implantation of the permanent device.

Related Conditions & MeSH terms

• Chronic Leg Pain
• Chronic Low-back Pain
• Low Back Pain

Intervention

Device:
• Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management
The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.

Locations

Country	Name	City	State
Australia	Genesis Research Services	Broadmeadow	New South Wales
Australia	Monash Clinical Research	Clayton	Victoria
Australia	Australian Medical Research	Hurstville	New South Wales
Australia	Sunshine Coast Clinical Research	Noosa Heads	Queensland
Australia	Sydney Pain Research Centre	Wahroonga	New South Wales

Sponsors (3)

Lead Sponsor	Collaborator
Biotronik, Inc.	Biotronik Australia Pty Ltd., BIOTRONIK Neuro

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Responder Rate to the BIOTRONIK Prospera SCS System Therapy	The purpose of primary endpoint 1 is to evaluate the overall responder rate of participants to the BIOTRONIK SCS Therapy at the 6-month follow-up interval. To be classified as a responder, a participant must achieve a reduction in overall pain intensity of at least a 50% from baseline, assessed using the Visual Analog Scale (VAS).	6 months post-implant
Primary	Primary Safety Information on the BIOTRONIK Prospera SCS System	The purpose of primary endpoint 2 is to collect primary safety information on the BIOTRONIK Prospera SCS System from permanent implant through the 6-month follow-up interval.	6 months post-implant